Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465184 | 0.82 | CYP11B1 (0.37) | KMT2ACYP11B1CYP11B2MEN1NPSR1 | |
| SCHEMBL3465188 | 0.77 | GABRA1 (0.36) | KMT2ACYP11B1CYP11B2MEN1 | |
| SCHEMBL3465242 | 0.75 | CYP11B1 (0.33) | KMT2AALDH1A1CYP11B1CYP11B2MEN1 | |
| SCHEMBL3466250 | 0.65 | CYP11B2 (0.44) | CYP11B1CYP11B2 | |
| SCHEMBL13160966 | 0.65 | MAPK1 (0.48) | KMT2AALDH1A1CYP11B1CYP11B2MEN1 | |
| SCHEMBL19763074 | 0.64 | CYP11B2 (0.43) | CYP11B1CYP11B2 | |
| SCHEMBL17894243 | 0.64 | CYP11B2 (0.42) | CYP11B1CYP11B2 | |
| SCHEMBL14415976 | 0.62 | CYP3A4 (0.52) | KMT2AMEN1MAPTMPOEPHX2 | |
| SCHEMBL22919816 | 0.61 | SMN1; SMN2 (0.35) | ALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL9823631 | 0.61 | MAPK1 (0.52) | KMT2AALDH1A1CYP11B1CYP11B2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262807-A1 | NOVEL TYROSINE KINASE INHIBITORS | ChemBridge Corporation (US) | 2010-12-22 | — | — | EP | disclosed |
| US-20100240641-A1 | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors | PAPILLON JULIEN | 2010-09-23 | — | — | US | disclosed |
| US-20100240641-A1 | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors | PAPILLON JULIEN | 2010-09-23 | — | — | US | disclosed |
| US-20100240641-A1 | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors | PAPILLON JULIEN | 2010-09-23 | — | — | US | disclosed |
| WO-2009117097-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| EP-2029604-A2 | ALDOSTERONE SYNTHASE AND/OR 11BETA-HYDROXYLASE INHIBITORS | Novartis AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007139992-A2 | ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240641-A1 | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors | HSD11B1, HSD11B2, CYP11B1 | KMT2A 2253/4885ALDH1A1 251/4885KDM4E 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.